Workflow
生物酶法合成
icon
Search documents
全球克拉维酸钾原料药总体规模及主要厂商占有率和排名
QYResearch· 2025-06-27 09:56
Core Viewpoint - The global market for potassium clavulanate API is projected to reach $700 million by 2031, with a compound annual growth rate (CAGR) of 5.2% in the coming years [1]. Market Overview - Potassium clavulanate is a β-lactamase inhibitor commonly used in combination with penicillin antibiotics, enhancing their antibacterial effectiveness [1]. - The market is primarily driven by the increasing demand for combination formulations due to rising antibiotic resistance [9]. Market Size and Growth - According to QYResearch, the global potassium clavulanate API market is expected to grow significantly, with the leading product being amoxicillin-clavulanate [6][8]. - The oral formulation segment accounts for approximately 74% of the market share, indicating a strong preference for this application [8]. Key Players - Major manufacturers in the potassium clavulanate API market include China National Pharmaceutical Group, GSK, Shandong New Era Pharmaceutical, and others, with the top three companies holding about 63% of the market share in 2024 [6][13]. Market Trends - The market is experiencing a shift towards green synthesis methods, such as enzyme-based processes, which are expected to replace traditional chemical methods, reducing energy consumption and pollution [8]. - The demand for potassium clavulanate is also bolstered by improvements in clinical recognition of its value in treating infectious diseases [9]. Challenges - The market faces challenges such as increasing environmental regulations that raise compliance costs for manufacturers [10]. - The emergence of new β-lactamase inhibitors poses a potential threat to the market share of potassium clavulanate [10]. - International trade barriers and varying regulatory standards across countries complicate market access and increase costs [10].